Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Method of regulating cell metabolism or physiology
Patent
1997-11-21
1999-08-31
Elliot, George C.
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Method of regulating cell metabolism or physiology
536 245, C07M 2100, C12N 506
Patent
active
059453362
ABSTRACT:
The present invention relates to methods of treating disease-associated cellular proliferation using oligonucleotides. In particular, it relates to the use of oligonulceotides which are substantially complementary to interleukin-6 receptor mRNA sequences. In the form of pharmaceutical compositions, these oligonucleotides are suitable for administration to human subjects for the treatment of abnormal cellular proliferation due to such diseases as cancer, autoimmune disorders and viral infection.
REFERENCES:
patent: 5225326 (1993-07-01), Bresser et al.
patent: 5252723 (1993-10-01), Bhatt
patent: 5470824 (1995-11-01), Miles et al.
patent: 5489519 (1996-02-01), Deeley et al.
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5716846 (1998-02-01), Brown et al.
Antisense '97: A roundtable on the state of the industry . Nature Biotechnology 15: 519-524.
Bangham, et al. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Med. Biol. 13:238-252 (1965).
Caruthers, et al. Chemical synthesis of deoxyoligonucleotides by the phosphoramidite method. Methods in Enzymology 154:287-313 Academic Press Inc. (1987).
Girasole, et al. Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. The Journal of Clinical Investigation, Inc. 89:883-891 (1992).
Grossman, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. 86:6367-6371 Medical Sciences (1989).
Hibi, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149-1157 Cell Press (1990).
Jilka, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257:88-91 (1992).
Klein, et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur. Cytokine Net., 1:193-201 (1990).
Levy, et al. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J. Clin. Invest. 88:696-699 The American Society for Clinical Investigation, Inc. (1991).
Majumdar, et al. Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide. Biochemistry 28:1340-1346 American Chemical Society (1989).
Milligan, et al. Development of antisense therapeutics. Implications for cancer gene therapy. Annals New York Academy of Sciences 716:228-241 (1994).
Scala, et al. Expression of an exogenous interleukin 6 gene in human epstein barr virus B cells confers growth advantage and in vivo tumorigencity. J. Exp. Med. 172:61-68 The Rockefeller University Press (1990).
Shuin, et al. The activity of topoisomerases is related to the grade and stage in human renal cell carcinoma. Anticancer Research 14(6B), 2621-2626 (1994.
Stec, et al. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides. J. Am. Chem. Soc. 106:6077-6079 American Chemical Society (1984).
Stein, et al. Phosphorothioate oligodeoxynucleotides-anti-sense inhibitors of gene expression. Pharmac. Ther. 52:365-384 Pergamon Press Ltd. Great Britain (1992).
Taga, et al. Receptors for B cell stimulatory factor 2 quantiation, specificity, distribution, and regulation of their expression. J. Exp. Med. 166:967-981 The Rockefeller University Press (1987).
Taga, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573-581 Cell Press (1989).
Takenawa, et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. Journal of the National Cancer Institute 83:1668-1672 (1991).
Vink, et al. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against Il-6 or its receptor. J. Exp. Med. 172:997-1000 The Rockefeller University Press (1990).
Ward, et al. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. The Journal of Biological Chemistry 269:23286-23289 The American Society for Biochemistry and Molecular Biology, Inc. U.S.A. (1994).
Yamasaki, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFNB 2 ) receptor. Science 241:825-828 (1988).
D'Hellencourt, et al., "Immunomodulation by cytokine antisense oligonucleotides", European Cytokine Network, 6(1):7-19, (1995).
Keller, et al., "Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells", J. Immunol., 154(8):4091-4098, (1995).
Reddy et al., "Interleukin-6 antisense deoxynucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone", J. Bone Miner. Res., 9(5):753-757, (1994).
Miller, et al., "Gene Transfer and Antisense Nucleic Acid Techniques", Parasitiology Today, 10(3):92-97, (Mar. 1994).
Stein, et al., "Antisense Oligonucleotides as Therapeutic Agents-Is the Bullet Really Magical", Science, 261:1004-1012, (Aug. 20, 1993).
Wu-Pong, S., "Oligonucleotides: Opportunities for Drug Therapy and Research", Pharmaceutical Technology, 18:102-114, (Oct. 1994).
Wagner, R., Gene inhibition using antisense oligodeoxynucleotides, Nature, 372:333-335, (Nov. 1994).
Weiss, R., "Upping the Antisense Ante", Science News, 139:108-109, (Feb. 16, 1991).
Bennett, F., "Antisense Research", Science, 271:434, (Jan. 26, 1996).
Uhlmann, et al., Antisense Oligonucleotides: A New Therapeutic Principle, Chemical Reviews, 90(4):543-584, (Jun. 1990).
Gewirtz et al., "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise." Proc. Natl. Acad. Sci. USA 93:3161-3163 (1996).
Gura, T., "Antisense Has Growing Pains." Science 270:575-577 (1995).
Keller et al., "Effect of IL-6 Receptor Antisense Oligodeoxynucleotide on In Vitro Proliferation of Myeloma Cells." J. Immunol. 154:4091-4098 (1995).
Milligan et al., "Current Consepts in Antisense Drug Design." Journal of Medical Chemistry 36(14):1923-1937 (1993).
Plenat, F., "Animal models of antisense oligonucleotides: lessons for use in humans." Molecular Medicine Today 2(6):250-257 (1996).
Rojanasakul, Y., "Antisense oligonucleotide therapeutics: drug delivery and targeting." Advanced Drug Design Reviews 18:115-131 (1996).
Stull et al., "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects." Pharmaceutical Research 12(4):465-483 (1995).
Zon et al., "Phosphorothioate oligonucleotides", Chapter Four in Oligonucleotides and Analogues: A Practical Approach, Eckstein, ed. IRL Press, pp. 87-108 (1991).
Brown Steven Joel
Dattagupta Nanibhushan
Naidu Yathi M.
Cappellari Charles B.
Elliot George C.
Gen-Probe Incorporated
Larson Thomas G.
LandOfFree
Oligonucleotides and methods for inhibiting cellular proliferati does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotides and methods for inhibiting cellular proliferati, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotides and methods for inhibiting cellular proliferati will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2426398